GMAB - Genmab: Ready For More Growth In 2022

• Genmab has an impressive pipeline of proprietary and partnered programs in development. In addition, the company has developed or helped develop five FDA-approved monoclonal antibody therapies.
• The company’s revenue is mostly recurring royalties and milestones through licensing of their novel and innovative technology. This business model creates steady revenue and long-term earnings growth.
• It looks as if the large payment from AbbVie has caused the market to misinterpret the company’s earnings, causing a strong sell-off from the November highs. I believe the market.
• I am looking to put GMAB into my “Bioreactor” growth portfolio for a long-term investment. I discuss my strategy for managing this position in the coming year.

For further details see: